DEGLI UBERTI, Ettore
 Distribuzione geografica
Continente #
NA - Nord America 23.474
EU - Europa 7.774
AS - Asia 4.941
SA - Sud America 27
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 7
OC - Oceania 6
Totale 36.247
Nazione #
US - Stati Uniti d'America 23.414
CN - Cina 2.701
DE - Germania 2.508
UA - Ucraina 1.930
TR - Turchia 1.117
SG - Singapore 1.022
IT - Italia 954
GB - Regno Unito 691
SE - Svezia 467
FI - Finlandia 459
RU - Federazione Russa 343
PL - Polonia 155
FR - Francia 94
BE - Belgio 70
CA - Canada 51
IR - Iran 24
NL - Olanda 22
ID - Indonesia 20
IN - India 18
BR - Brasile 17
LT - Lituania 16
EU - Europa 14
CZ - Repubblica Ceca 11
IE - Irlanda 11
RO - Romania 10
VN - Vietnam 10
JP - Giappone 9
MA - Marocco 6
MX - Messico 6
DK - Danimarca 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AU - Australia 4
CH - Svizzera 4
ES - Italia 4
HK - Hong Kong 4
PE - Perù 4
PT - Portogallo 4
AT - Austria 3
EC - Ecuador 3
BD - Bangladesh 2
CY - Cipro 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
IQ - Iraq 2
KZ - Kazakistan 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BG - Bulgaria 1
CL - Cile 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
KR - Corea 1
LU - Lussemburgo 1
MC - Monaco 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
PS - Palestinian Territory 1
RS - Serbia 1
TH - Thailandia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 36.247
Città #
Woodbridge 3.027
Fairfield 2.448
Jacksonville 2.158
Chandler 2.078
Ashburn 1.734
Houston 1.721
Ann Arbor 1.271
Wilmington 950
Seattle 938
Santa Clara 859
Singapore 784
Cambridge 747
Izmir 676
Nanjing 616
Beijing 545
Princeton 439
Addison 384
San Diego 275
Boardman 267
Milan 204
Shenyang 198
Shanghai 190
Nanchang 180
New York 164
Dearborn 163
Warsaw 154
Ferrara 135
Hebei 134
Los Angeles 123
Changsha 112
Bremen 109
Tianjin 107
Washington 107
Jiaxing 97
Jinan 80
Falls Church 69
Mountain View 67
Brussels 64
San Mateo 62
Helsinki 60
London 52
Kunming 47
Norwalk 47
Ningbo 45
Zhengzhou 45
Redwood City 44
Guangzhou 41
Carrara 40
Munich 39
Auburn Hills 36
Tappahannock 36
Taizhou 34
Leawood 30
Orange 28
Düsseldorf 27
Toronto 27
Des Moines 26
Frankfurt am Main 25
Indiana 25
Hefei 24
Augusta 22
Hangzhou 21
Jakarta 20
Verona 20
Monmouth Junction 18
Ardabil 17
Philadelphia 17
Lanzhou 15
Bologna 14
Rome 14
Changchun 13
Ferrara di Monte Baldo 12
Ottawa 12
Haikou 11
Padova 10
Redmond 10
Chengdu 9
Dong Ket 9
Kilburn 8
Mumbai 8
San Francisco 8
Walnut 8
Yellow Springs 8
Hounslow 7
Prescot 7
Chicago 6
Dallas 6
Fuzhou 6
Castelnuovo Rangone 5
Dublin 5
Naples 5
Olomouc 5
Tangier 5
Edinburgh 4
Genoa 4
Jinhua 4
Lima 4
Messina 4
Pisa 4
Taiyuan 4
Totale 25.603
Nome #
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 340
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 240
Igf-I influences everolimus activity in medullary thyroid carcinoma 166
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 164
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 161
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses 160
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 159
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 157
Role of Ultrasonographic/Clinical Profile, Cytology, and BRAF V600E Mutation Evaluation in Thyroid Nodule Screening for Malignancy: A Prospective Study 155
Circadian profile of plasma calcitonin gene-related peptide in healthy man 154
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 148
Relevance of BRAF(V600E) Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer 147
Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection 146
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 143
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 143
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 142
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 141
ROLL technique application for Minimally-Invasive Radioguided Parathyroidectomy (MIRP) in Hyperparathyroidism (HPT) 140
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 139
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 138
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 136
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors 136
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 134
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 132
Characterization of a deleted Y chromosome in a male with Turner stigmata 132
Differences in blood pressure regulation of congestive heart failure, before and after treatment, correlate with changes in the circulating pattern of atrial natriuretic peptide 131
Consistent changes in the circadian rhythms of blood pressure and atrial natriuretic peptide in congestive heart failure 131
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 131
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 131
null 130
Atrial natriuretic peptide and circadian blood pressure regulation: clues from a chronobiological approach 129
Functional characterization of a new deletion in CDKN1B 5'-UTR region 127
Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects 127
The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF 127
Effect of ketanserin, an inhibitor of 5-HT2 receptors, on the aldosterone-stimulating action of metoclopramide 126
Circadian rhythms of atrial natriuretic peptide, blood pressure and heart rate in normal subjects 125
Pituitary side effects of old and new drugs. 125
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 125
Cerebral aneurysm and acromegaly: a case report 124
Stimulatory effect of dermorphin, a new synthetic potent opiate-like peptide, on human growth hormone secretion 124
Atrial strain is the main determinant of release of atrial natriuretic peptide 123
Role of the serotonergic system in the genesis of vasovagal syncope. 123
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 123
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 122
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 122
Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects 121
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 121
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 121
Post-partum thyroiditis - A clinical update 120
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 120
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine needle aspiration biopsies. 120
Epidermal growth factor pathway as a possible target in the medical therapy of bronchial carcinoids 120
In vitro testing of new somatostatin analogs on pituitary tumor cells 119
Rare diseases in clinical endocrinology: a taxonomic classification system. 119
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. 119
Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. 119
HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis 119
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 119
null 118
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 118
Responses of plasma renin activity, aldosterone, adrenocorticotropin, and cortisol to dermorphin, a new synthetic potent opiate-like peptide, in man 118
Different levels of thyroglobulin mRNA in normal and neoplastic human thyroids 118
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto’s thyroiditis 118
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. 118
L’iperplasia surrenale congenita e la pubertà precoce 117
Should aip gene screening be recommended in family members of FIPA patients with R16H variant? 117
Magmas, a Novel Over-Expressed Gene in Pituitary Rat Cell Lines and in Human Pituitary Adenomas: A New Pituitary Biomarker? 117
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 116
Cholinergic mediation in dermorphin-induced growth hormone secretion in man 116
Iodine excess and hyperthyroidism 115
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. 115
Growth hormone and skeletal muscle function 115
mTOR mediated IGF1 proliferative effects on a rat pituitary GH/PRL secreting pituitary adenoma cell line 115
null 114
Dermorphin inhibits spinal nociceptive flexion reflex in humans 114
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 114
Prolactin-Releasing Activity of Dermorphin, a New Synthetic Potent Opiate-Like Peptide, in Normal Human Subjects 114
Progressive disruption of the circadian rhythm of melatonin in fatal familial insomnia 113
Effect of dermorphin on behavior and hippocampal electrical activity in rabbits 113
null 113
Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure 113
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 113
Growth hormone excess promotes breast cancer chemoresistance 113
Magmas, a novel over-expressed gene in Pituitary rat cell lines and in human pituitary adenomas: a new pituitary bio marker? 112
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 112
miR-15a and miR-16-1 down-regulation in pituitary adenomas 112
Does placebo lower blood pressure in hypertensive patients? A noninvasive chronobiological study 111
null 111
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 111
null 111
Evidence for androgen receptor gene expression in human thyroid cells and tumours 111
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma 110
Changes of plasma calcitonin gene-related peptide levels in postmenopausal women 110
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 109
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 109
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 109
Utilization of luminescent technology to develop a kinase assay: Cdk4 as a model system 109
MTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors 109
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells 109
null 108
Totale 12.794
Categoria #
all - tutte 158.557
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 10.299
Totale 168.856


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.334 0 0 0 0 424 884 545 715 447 827 395 97
2020/20214.416 463 380 205 586 164 495 115 520 68 522 688 210
2021/20224.080 129 416 246 180 192 186 164 183 164 338 437 1.445
2022/20234.399 443 303 175 595 687 658 179 383 578 32 214 152
2023/20242.338 200 274 132 62 204 382 71 462 40 28 34 449
2024/20252.289 230 180 625 210 1.044 0 0 0 0 0 0 0
Totale 36.558